Lack of Progress in Early Diagnosis of Bladder Cancer

Motoo Araki, Alan M. Nieder, Murugesan Manoharan, Yulong Yang, Mark S. Soloway

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objectives: The stage of presentation of prostate cancer has changed dramatically in the past two decades, largely because of prostate-specific antigen screening and increased public awareness regarding the disease. Recently, strides have been made in the validation, development, and approval of bladder cancer (BC) markers. We sought to evaluate whether any stage migration has occurred for patients with BC during the same period. Methods: A total of 351 and 1262 patients underwent radical cystectomy and radical retropubic prostatectomy, respectively, between 1992 and 2005 by one surgeon. The patients were divided into two consecutive groups: group 1 (1992 to 1998) and group 2 (1999 to 2005). The baseline and pathologic characteristics of the patients were compared. Results: No differences were found in the clinical or pathologic staging between the two groups of patients undergoing radical cystectomy. The 5-year overall and disease-specific survival also was not different between the two groups. For patients with prostate cancer, those in group 2 presented at a younger age, with a lower prostate-specific antigen level, and had a lower clinical stage. Group 2 patients had a decrease in the incidence of extracapsular extension, a decreased tumor volume, and a decrease in the incidence of Gleason 8 to 10 tumors. Conclusions: During two consecutive periods, our patients with prostate cancer presented with the cancer at an earlier stage and had more favorable pathologic features after radical retropubic prostatectomy. However, our patients with BC did not demonstrate any stage migration. Physicians need to be more aggressive in diagnosing BC, especially in patients at high risk of the disease. Risk factors must be emphasized, urine markers should be used in a screening strategy, and the indications for radical cystectomy should be liberalized.

Original languageEnglish
Pages (from-to)270-274
Number of pages5
JournalUrology
Volume69
Issue number2
DOIs
StatePublished - Feb 1 2007

Fingerprint

Early Detection of Cancer
Urinary Bladder Neoplasms
Cystectomy
Prostatic Neoplasms
Prostate-Specific Antigen
Prostatectomy
Incidence
Tumor Burden
Neoplasms
Urine
Physicians
Survival

ASJC Scopus subject areas

  • Urology

Cite this

Araki, M., Nieder, A. M., Manoharan, M., Yang, Y., & Soloway, M. S. (2007). Lack of Progress in Early Diagnosis of Bladder Cancer. Urology, 69(2), 270-274. https://doi.org/10.1016/j.urology.2006.10.016

Lack of Progress in Early Diagnosis of Bladder Cancer. / Araki, Motoo; Nieder, Alan M.; Manoharan, Murugesan; Yang, Yulong; Soloway, Mark S.

In: Urology, Vol. 69, No. 2, 01.02.2007, p. 270-274.

Research output: Contribution to journalArticle

Araki, M, Nieder, AM, Manoharan, M, Yang, Y & Soloway, MS 2007, 'Lack of Progress in Early Diagnosis of Bladder Cancer', Urology, vol. 69, no. 2, pp. 270-274. https://doi.org/10.1016/j.urology.2006.10.016
Araki M, Nieder AM, Manoharan M, Yang Y, Soloway MS. Lack of Progress in Early Diagnosis of Bladder Cancer. Urology. 2007 Feb 1;69(2):270-274. https://doi.org/10.1016/j.urology.2006.10.016
Araki, Motoo ; Nieder, Alan M. ; Manoharan, Murugesan ; Yang, Yulong ; Soloway, Mark S. / Lack of Progress in Early Diagnosis of Bladder Cancer. In: Urology. 2007 ; Vol. 69, No. 2. pp. 270-274.
@article{33669a29ea8a4563991254b401b2cec1,
title = "Lack of Progress in Early Diagnosis of Bladder Cancer",
abstract = "Objectives: The stage of presentation of prostate cancer has changed dramatically in the past two decades, largely because of prostate-specific antigen screening and increased public awareness regarding the disease. Recently, strides have been made in the validation, development, and approval of bladder cancer (BC) markers. We sought to evaluate whether any stage migration has occurred for patients with BC during the same period. Methods: A total of 351 and 1262 patients underwent radical cystectomy and radical retropubic prostatectomy, respectively, between 1992 and 2005 by one surgeon. The patients were divided into two consecutive groups: group 1 (1992 to 1998) and group 2 (1999 to 2005). The baseline and pathologic characteristics of the patients were compared. Results: No differences were found in the clinical or pathologic staging between the two groups of patients undergoing radical cystectomy. The 5-year overall and disease-specific survival also was not different between the two groups. For patients with prostate cancer, those in group 2 presented at a younger age, with a lower prostate-specific antigen level, and had a lower clinical stage. Group 2 patients had a decrease in the incidence of extracapsular extension, a decreased tumor volume, and a decrease in the incidence of Gleason 8 to 10 tumors. Conclusions: During two consecutive periods, our patients with prostate cancer presented with the cancer at an earlier stage and had more favorable pathologic features after radical retropubic prostatectomy. However, our patients with BC did not demonstrate any stage migration. Physicians need to be more aggressive in diagnosing BC, especially in patients at high risk of the disease. Risk factors must be emphasized, urine markers should be used in a screening strategy, and the indications for radical cystectomy should be liberalized.",
author = "Motoo Araki and Nieder, {Alan M.} and Murugesan Manoharan and Yulong Yang and Soloway, {Mark S.}",
year = "2007",
month = "2",
day = "1",
doi = "10.1016/j.urology.2006.10.016",
language = "English",
volume = "69",
pages = "270--274",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Lack of Progress in Early Diagnosis of Bladder Cancer

AU - Araki, Motoo

AU - Nieder, Alan M.

AU - Manoharan, Murugesan

AU - Yang, Yulong

AU - Soloway, Mark S.

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Objectives: The stage of presentation of prostate cancer has changed dramatically in the past two decades, largely because of prostate-specific antigen screening and increased public awareness regarding the disease. Recently, strides have been made in the validation, development, and approval of bladder cancer (BC) markers. We sought to evaluate whether any stage migration has occurred for patients with BC during the same period. Methods: A total of 351 and 1262 patients underwent radical cystectomy and radical retropubic prostatectomy, respectively, between 1992 and 2005 by one surgeon. The patients were divided into two consecutive groups: group 1 (1992 to 1998) and group 2 (1999 to 2005). The baseline and pathologic characteristics of the patients were compared. Results: No differences were found in the clinical or pathologic staging between the two groups of patients undergoing radical cystectomy. The 5-year overall and disease-specific survival also was not different between the two groups. For patients with prostate cancer, those in group 2 presented at a younger age, with a lower prostate-specific antigen level, and had a lower clinical stage. Group 2 patients had a decrease in the incidence of extracapsular extension, a decreased tumor volume, and a decrease in the incidence of Gleason 8 to 10 tumors. Conclusions: During two consecutive periods, our patients with prostate cancer presented with the cancer at an earlier stage and had more favorable pathologic features after radical retropubic prostatectomy. However, our patients with BC did not demonstrate any stage migration. Physicians need to be more aggressive in diagnosing BC, especially in patients at high risk of the disease. Risk factors must be emphasized, urine markers should be used in a screening strategy, and the indications for radical cystectomy should be liberalized.

AB - Objectives: The stage of presentation of prostate cancer has changed dramatically in the past two decades, largely because of prostate-specific antigen screening and increased public awareness regarding the disease. Recently, strides have been made in the validation, development, and approval of bladder cancer (BC) markers. We sought to evaluate whether any stage migration has occurred for patients with BC during the same period. Methods: A total of 351 and 1262 patients underwent radical cystectomy and radical retropubic prostatectomy, respectively, between 1992 and 2005 by one surgeon. The patients were divided into two consecutive groups: group 1 (1992 to 1998) and group 2 (1999 to 2005). The baseline and pathologic characteristics of the patients were compared. Results: No differences were found in the clinical or pathologic staging between the two groups of patients undergoing radical cystectomy. The 5-year overall and disease-specific survival also was not different between the two groups. For patients with prostate cancer, those in group 2 presented at a younger age, with a lower prostate-specific antigen level, and had a lower clinical stage. Group 2 patients had a decrease in the incidence of extracapsular extension, a decreased tumor volume, and a decrease in the incidence of Gleason 8 to 10 tumors. Conclusions: During two consecutive periods, our patients with prostate cancer presented with the cancer at an earlier stage and had more favorable pathologic features after radical retropubic prostatectomy. However, our patients with BC did not demonstrate any stage migration. Physicians need to be more aggressive in diagnosing BC, especially in patients at high risk of the disease. Risk factors must be emphasized, urine markers should be used in a screening strategy, and the indications for radical cystectomy should be liberalized.

UR - http://www.scopus.com/inward/record.url?scp=33847055912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847055912&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2006.10.016

DO - 10.1016/j.urology.2006.10.016

M3 - Article

VL - 69

SP - 270

EP - 274

JO - Urology

JF - Urology

SN - 0090-4295

IS - 2

ER -